 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Multiple Myeloma
| Alkylade (0-6-benzylguanine) |
AGT inhibitor |
Access Oncology, Pacific Pharmaceuticals |
II |
| AP1903 |
Gene therapy |
Ariad Pharmaceuticals |
II |
| Atiprimod |
CyP2006b inhibitor |
Callesto |
I |
| Brevarex (oregovomab) |
MoAb against MVC1 |
Alta Rex Corporation United Therapeutics |
I |
| Doxil (liposomal doxorubicin) |
Anthracycline |
Ortho Biotech |
III |
| HuN901-DM |
MoAb anti CD56 |
ImmunoGen |
I |
| MG98 |
Antisense |
MethylGene |
I |
| Mylovenge |
Vaccine |
Dendreon |
II |
| Panzem (2-methoxyestradiol) |
Estrogen |
EntreMed |
II |
| PI-88 |
Antiangiogensis |
Progen Therapeutics |
II |
| Revlimid (lenlalidomide) |
Immunomodulator |
Celgene |
FDA Submission 4-8-05 Pending approval |
| Thalomid (thalidomide) |
antiangiogenisis |
Celgene |
III |
| Tiazole (tiazofurin) |
Tiazole (tiazofurin) |
ICN Pharmaceuticals |
II |
| Zarnestra (tipifarnib) |
Farensyl transferase inhibitor |
Johnson & Johnson |
II |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
